





























![]()
Q1: 2026-05-04 Earnings Summary
EPS of -$0.05 beats by $0.07
|
Revenue of
$73.14M
(6.74% Y/Y)
beats by $967.33K
Evolus, Inc. (EOLS) Q1 2026 Earnings Call May 4, 2026 4:30 PM EDT
Company Participants
Nareg Sagherian - Head of Global Investor Relations & Corporate Communications
David Moatazedi - President, CEO & Director
Tatjana Mitchell - Chief Financial Officer
Rui Avelar - Chief Medical Officer and Head of Research & Development
Conference Call Participants
Annabel Samimy - Stifel, Nicolaus & Company, Incorporated, Research Division
Marc Goodman - Leerink Partners LLC, Research Division
Uy Ear - Mizuho Securities USA LLC, Research Division
Navann Ty Dietschi - BNP Paribas, Research Division
Douglas Tsao - H.C. Wainwright & Co, LLC, Research Division
Sam Eiber - BTIG, LLC, Research Division
Serge Belanger - Needham & Company, LLC, Research Division
Presentation
Operator
Good afternoon, everyone, and thank you for standing by. Welcome to Evolus First Quarter Earnings Conference Call. [Operator Instructions] As a reminder, today's conference is being recorded and webcast live. [Operator Instructions]
I would now like to turn the conference over to Nareg Sagherian, Vice President, Head of Investor Relations and Corporate Communications. Please go ahead.
Nareg Sagherian
Head of Global Investor Relations & Corporate Communications
Thank you, operator, and welcome to everyone joining us on today's call to review Evolus' first quarter financial results. Our first quarter press release is now on our website at evolus.com. With me today are David Moatazedi, President and Chief Executive Officer; Tatjana Mitchell, Chief Financial Officer; and Rui Avelar, Chief Medical Officer and Head of R&D, is also with us for the Q&A portion of the call.
Today's call will include forward-looking statements. Actual results may differ materially due to risks and uncertainties outlined in our earnings press release and SEC filings. These forward-looking statements are based on current assumptions, and we undertake no obligation to update them. Additionally, we will discuss certain non-GAAP financial measures. These measures should be considered in addition to and not as a substitute
此内容由惯性聚合(RSS阅读器)自动聚合整理,仅供阅读参考。 原文来自 — 版权归原作者所有。